Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
Companies To Watch: Equillium
Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.
Companies To Watch: Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.
Companies To Watch: argenx
Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.
Companies To Watch: Neurana
This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.
Companies To Watch: Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.
Companies To Watch: Imago BioSciences
In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.
Companies To Watch: Scynexis
Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.
Companies To Watch: Obsidian Therapeutics
Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.
Companies To Watch: eXIthera
This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.
Companies To Watch: Leading Biosciences
Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.
Companies To Watch: Bioharmony Therapeutics
Bioharmony Therapeutics is developing novel, “lysin-based” antimicrobials. The company is out to change the world of antibiotics, not by tweaking an old formula, but by advancing an entirely new mode of action.
Companies To Watch: Angion
Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.
Companies To Watch: Synlogic
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
Companies To Watch: Provention Bio
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
BEYOND THE PRINTED PAGE
Lawrence Blatt: Biopharma Entrepreneur And Professional Musician
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, his latest biopharma entrepreneurial venture, provides insight into the music industry, as he happens to also be a professional musician.
A Biopharma CEO Not Focused On Stock Price
BioNTech’s founder and CEO, Ugur Sahin, M.D., Ph.D., subject of an upcoming feature in Life Science Leader, provides perspective on the company’s IPO and stock price as a metric.
Disappointments In Alzheimer’s Therapeutic Development — A Conversation With John LaMattina
A question from a reader for Life Science Leader's popular monthly Ask The Board column, prompts a Q&A discussion with John LaMattina, Ph.D., on the retreat from neuroscience R&D.
LIFE SCIENCE LEADER BLOGS
Readying For A Virtual Fireside Chat With A Biomanufacturing Icon
Biomanufacturing icon Andy Skibo, and Life Science Leader chief editor Rob Wright, on topics and planning for upcoming fireside chat at the American Biomanufacturing Summit 2020 that has now gone virtual.
BIO Digital Makes The Best Of A Bad COVID-19 Situation
Life Science Leader’s Rob Wright provides perspective on BIO Digital 2020, and a recommendation for the session every BIO Digital registered attendee should make time to attend.